LY364947: Selective TGF-β Type I Receptor Kinase Inhibitor for EMT and Preclinical Research

Executive Summary: LY364947 is a chemically defined, selective inhibitor of the TGF-β type I receptor kinase domain (IC₅₀ = 51 nM), used primarily to interrogate TGF-β-dependent signaling in preclinical models (ApexBio). It robustly blocks Smad2 phosphorylation and suppresses EMT markers such as fibronectin and vimentin, while restoring E-cadherin expression in cellular assays (Gu et al., 2025). In vivo, LY364947 mitigates retinal degeneration and vascular damage in NMDA-induced rat models. Its solubility profile (DMSO ≥ 24.4 mg/mL; insoluble in water/ethanol) makes it suitable for diverse assay platforms. LY364947 is intended exclusively for scientific research and not for clinical or diagnostic use.

Biological Rationale

The transforming growth factor-β (TGF-β) pathway is a central regulator of cellular processes including proliferation, differentiation, extracellular matrix (ECM) deposition, and immune modulation (Strategic Targeting of the TGF-β Pathway). Dysregulation of TGF-β signaling is implicated in the pathogenesis of fibrosis, cancer progression, and retinal degeneration. One key downstream effect is the induction of epithelial-mesenchymal transition (EMT), a process marked by loss of epithelial markers (e.g., E-cadherin) and gain of mesenchymal markers (e.g., vimentin, fibronectin), leading to enhanced cell migration and invasiveness. Selective inhibition of the TGF-β type I receptor kinase provides a targeted approach to dissecting these mechanisms in research contexts. Previous reviews have highlighted the broad utility of TGF-β inhibitors but have not provided the mechanistic and benchmark-focused synthesis available here (LY364947 and the Future of TGF-β Pathway Modulation).

Mechanism of Action of LY364947

LY364947 (4-(5-pyridin-2-yl-1H-pyrazol-4-yl)quinoline; MW 272.3; C₁₇H₁₂N₄) is a small molecule that acts as a selective ATP-competitive inhibitor of the TGF-β type I receptor (ALK5) kinase domain. By binding to the kinase active site, it prevents phosphorylation of Smad2/3, the canonical downstream effectors of the TGF-β pathway (Gu et al., 2025). This leads to suppression of TGF-β-induced EMT, as evidenced by decreased expression of mesenchymal markers (fibronectin, vimentin) and re-expression of epithelial markers (E-cadherin). In cellular models, such as HOXB9-MCF10A, LY364947 reduces cell migration and invasiveness. Unlike broader kinase inhibitors, LY364947 exhibits high selectivity for ALK5, minimizing off-target effects in experimental systems (LY364947 in Preclinical Research). This mechanistic specificity allows for precise dissection of TGF-β pathway functions in oncology, fibrosis, and ocular disease models.

Evidence & Benchmarks

• LY364947 inhibits TGF-β type I receptor kinase activity with an IC₅₀ of 51 nM in enzymatic assays (ApexBio, product data).
• In HOXB9-MCF10A cell models, LY364947 blocks Smad2 phosphorylation and suppresses EMT marker expression (fibronectin, vimentin) while restoring E-cadherin (Gu et al., 2025, DOI).
• LY364947 reduces cell migration and invasiveness in vitro, providing a benchmark for anti-EMT agents (Gu et al., 2025).
• In rat NMDA-induced retinal degeneration models, LY364947 administration attenuates neuronal loss and vascular damage, indicating neuroprotective properties (ApexBio, product data).
• Compared to non-selective kinase inhibitors, LY364947 demonstrates minimal off-target kinase inhibition in panel screens (LY364947: Next-Generation TGF-β Inhibitor).

Applications, Limits & Misconceptions

LY364947 is widely used as a tool compound for:

• Dissecting TGF-β/Smad2/3 signaling in preclinical models of EMT, fibrosis, and cancer.
• Studying the impact of TGF-β pathway modulation on cell migration, invasion, and ECM remodeling.
• Evaluating anti-fibrotic strategies in organotypic and in vivo models.
• Testing pathway crosstalk, e.g., with Wnt/β-catenin or CDK4/6 inhibitors (Gu et al., 2025).
• Assessing neurovascular protection in retinal degeneration models.

For more advanced mechanistic design and comparison with other TGF-β inhibitors, see our contrast with LY364947: Selective TGF-β Type I Receptor Kinase Inhibitor Overview, which provides a broader overview, while this article delivers deeper benchmarking and workflow specifics.

Common Pitfalls or Misconceptions

• LY364947 is not clinically validated and is strictly for research use; it is not approved for diagnostic or therapeutic purposes.
• The compound is insoluble in water and ethanol; improper solvent selection can lead to precipitation and assay failure.
• LY364947 selectively inhibits TGF-β type I receptor kinase and does not block other TGF-β receptor subtypes or unrelated kinases at research concentrations.
• Extended storage of LY364947 solutions (>1 week at room temperature) may result in compound degradation; fresh DMSO solutions are recommended for optimal activity.
• In vivo efficacy is context-dependent and may not generalize across all fibrotic or degenerative models without dose optimization.

Workflow Integration & Parameters

For experimental use, LY364947 is supplied as a DMSO stock solution (≥24.4 mg/mL) and should be stored at –20°C. Working solutions should be freshly prepared or used within a short-term window (<7 days) to maintain compound integrity. Typical in vitro concentrations range from 0.1–10 μM, depending on cell type and assay sensitivity (ApexBio). Solubility in DMSO enables compatibility with most cell-based and biochemical assays. Researchers should confirm cellular uptake and pathway inhibition via Smad2/3 phosphorylation status. For in vivo studies, vehicle and dose selection must account for DMSO tolerability and compound pharmacokinetics. See also LY364947 in Preclinical Research for best practices in dosing and formulation; this resource is extended here with new evidence and more granular workflow recommendations.

Conclusion & Outlook

LY364947 (B2287) remains a gold-standard, selective TGF-β type I receptor kinase inhibitor for preclinical research. Its robust inhibition of Smad2 phosphorylation and EMT markers, combined with a favorable selectivity profile, make it invaluable for dissecting TGF-β signaling in oncology, fibrosis, and neurovascular models. While not suitable for clinical or diagnostic use, LY364947 is central to the development of next-generation anti-fibrotic and anti-metastatic strategies. Future research will clarify its utility in combinatorial regimens, such as with CDK4/6 or BET inhibitors, as highlighted by recent mechanistic studies (Gu et al., 2025).